Boston, MA – (NYSEPOST) - 04/07/2014 – Nuvilex Inc (OTCMKTS:NVLX) stated that it will be working with the Translational Drug Development/TD2 & Dr. Daniel Von Hoff, the leading figure in the world, for pancreatic cancer, to develop the company’s pancreatic cancer & other treatments using Cell-in-a- Box technology. Nuvilex Inc (OTCMKTS:NVLX)’s announcement was filled with a numerous monumental headlines. The company announced that the Translational Drug Development/ TD2 will now conduct preclinical & clinical studies for Nuvilex Inc (OTCMKTS:NVLX) that seem to be aimed at overall management of pancreatic-cancer.
Dr. Daniel Von Hoff who had just led NASDAQs’ – Celgene to Food & Drug Development approval for the advanced inoperable pancreatic-cancer treatment will now be playing a pivotal role in the Nuvilex Inc (OTCMKTS:NVLX) studies. Nuvilex Inc (OTCMKTS:NVLX) has access to the TD2’s Pancreatic-Cancer Research Team that is made up of 65 Oncology Clinicians and Surgeons as well as Researchers who are the member-investigators of PCRT & who represent 45 different clinical-research sites globally. This is definitely good news for the company .
It has attracted Dr. Daniel Von Hoff, the world-renowned oncologist & that is not a small feat given that he is probably very selective about projects that he works within the pancreatic cancer, this is a field that he has been writing about for years. The Dr. Daniel Nuvilex Inc (OTCMKTS:NVLX) team presents a new tool to employ against all the symptoms and the invasive properties of this extremely challenging cancer said the Chief Development Officer of the TD2, Daniel D. Von Hoff.
He said that the Pancreatic Cancer Research Team colleagues are very enthusiastic to start on the clinical trials with this particular approach. Nuvilex, Inc. operates independently and through wholly owned subsidiaries. Nuvilex Inc (OTCMKTS:NVLX) is a bio tech & life technology company and specializes in living-cell-encapsulation. The company is focused on the preparations for a latest pancreatic cancer clinical-trial via live-cell encapsulation of the chemotherapeutic-converting cells.